9636 related articles for article (PubMed ID: 15807627)
21. Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C.
Malov SI; Malov IV; Kuvshinov AG; Marche PN; Decaens T; Macek-Jilkova Z; Yushchuk ND
Sovrem Tekhnologii Med; 2021; 13(1):27-33. PubMed ID: 34513063
[TBL] [Abstract][Full Text] [Related]
22. Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for alpha-fetoprotein-producing gastric carcinoma.
Hishinuma M; Ohashi KI; Yamauchi N; Kashima T; Uozaki H; Ota S; Kodama T; Aburatani H; Fukayama M
Histopathology; 2006 Nov; 49(5):479-86. PubMed ID: 17064293
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
25. Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR.
Yan D; He Q; Chen Y; Wang L; Zhang X
J Clin Lab Anal; 2011; 25(2):113-7. PubMed ID: 21438004
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma.
Lee HJ; Yeon JE; Suh SJ; Lee SJ; Yoon EL; Kang K; Yoo YJ; Kim JH; Seo YS; Yim HJ; Byun KS
Gut Liver; 2014 Mar; 8(2):177-85. PubMed ID: 24672660
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma.
Yoshida S; Kurokohchi K; Arima K; Masaki T; Hosomi N; Funaki T; Murota M; Kita Y; Watanabe S; Kuriyama S
Int J Oncol; 2002 Feb; 20(2):305-9. PubMed ID: 11788893
[TBL] [Abstract][Full Text] [Related]
28. Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma.
Yu JP; Xu XG; Ma RJ; Qin SN; Wang CR; Wang XB; Li M; Li MS; Ma Q; Xu WW
J Clin Lab Anal; 2015 Mar; 29(2):85-93. PubMed ID: 24687454
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis.
Jia X; Liu J; Gao Y; Huang Y; Du Z
Arch Med Res; 2014 Oct; 45(7):580-8. PubMed ID: 25446613
[TBL] [Abstract][Full Text] [Related]
30. Serological markers of liver cancer.
Yuen MF; Lai CL
Best Pract Res Clin Gastroenterol; 2005 Feb; 19(1):91-9. PubMed ID: 15757806
[TBL] [Abstract][Full Text] [Related]
31. [The value of serum glypican-3 level in aided diagnosis of patients with primary hepatocellular carcinoma].
Tang XY; Wang YC; Lu RQ; Guo L
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):998-1002. PubMed ID: 32907292
[No Abstract] [Full Text] [Related]
32. Development and
Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma.
Ozkan H; Erdal H; Koçak E; Tutkak H; Karaeren Z; Yakut M; Köklü S
J Clin Lab Anal; 2011; 25(5):350-3. PubMed ID: 21919070
[TBL] [Abstract][Full Text] [Related]
34. Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis.
Xu D; Su C; Sun L; Gao Y; Li Y
Ann Hepatol; 2019; 18(1):58-67. PubMed ID: 31113610
[TBL] [Abstract][Full Text] [Related]
35. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
[TBL] [Abstract][Full Text] [Related]
36. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
37. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma.
Hippo Y; Watanabe K; Watanabe A; Midorikawa Y; Yamamoto S; Ihara S; Tokita S; Iwanari H; Ito Y; Nakano K; Nezu J; Tsunoda H; Yoshino T; Ohizumi I; Tsuchiya M; Ohnishi S; Makuuchi M; Hamakubo T; Kodama T; Aburatani H
Cancer Res; 2004 Apr; 64(7):2418-23. PubMed ID: 15059894
[TBL] [Abstract][Full Text] [Related]
38. [The clinical value of serum GPC3 level in predicting recurrence of patients with primary hepatocellular carcinoma].
Zhang PR; Ma XL; Guo L; Lu RQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jun; 57(6):885-890. PubMed ID: 37357208
[No Abstract] [Full Text] [Related]
39. Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients.
Li B; Liu H; Shang HW; Li P; Li N; Ding HG
Afr Health Sci; 2013 Sep; 13(3):703-9. PubMed ID: 24250310
[TBL] [Abstract][Full Text] [Related]
40. [Clinical usefulness of lectin-reactive fraction of alpha-fetoprotein in hepatocellular carcinoma].
Tamura A; Oita T; Sakizono K; Nakajima T; Kasakura S
Rinsho Byori; 1998 Feb; 46(2):158-62. PubMed ID: 9528340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
